Although less frequent, an association between BRAF/MEKi and cardiovascular or hematological side effects such as heart failure (reported odds ratio [ROR] = 1.62 compared to BRAF inhibitor monotherapy), venous (ROR = 1.8) and pulmonary thromboembolism (ROR = 1.91) or anemia (occurred in 10.5–22% of the patients treated) have been demonstrated [13, 14]. Here, BRAF is linked to anemia (phenotype).